Free Trial
NASDAQ:APTO

Aptose Biosciences (APTO) Stock Price, News & Analysis

Aptose Biosciences logo

About Aptose Biosciences Stock (NASDAQ:APTO)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.71
$6.86
52-Week Range
N/A
Volume
650,294 shs
Average Volume
227,964 shs
Market Capitalization
$3.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Strong Buy

Company Overview

Aptose Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
24th Percentile Overall Score

APTO MarketRank™: 

Aptose Biosciences scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aptose Biosciences has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aptose Biosciences has received no research coverage in the past 90 days.

  • Read more about Aptose Biosciences' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aptose Biosciences is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aptose Biosciences is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for APTO.
  • Dividend Yield

    Aptose Biosciences does not currently pay a dividend.

  • Dividend Growth

    Aptose Biosciences does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for APTO.
  • MarketBeat Follows

    1 people have added Aptose Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aptose Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.33% of the stock of Aptose Biosciences is held by insiders.

  • Percentage Held by Institutions

    Only 26.62% of the stock of Aptose Biosciences is held by institutions.

  • Read more about Aptose Biosciences' insider trading history.
Receive APTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APTO Stock News Headlines

Aptose Upgraded to Trade on OTCQB Market
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
Aptose Provides Corporate Updates
APTOF Aptose Biosciences Inc.
See More Headlines

APTO Stock Analysis - Frequently Asked Questions

Aptose Biosciences Inc. (NASDAQ:APTO) posted its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($12.90) EPS for the quarter, beating analysts' consensus estimates of ($17.40) by $4.50.

Aptose Biosciences's stock reverse split on Wednesday, February 26th 2025.The 1-30 reverse split was announced on Tuesday, February 18th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aptose Biosciences investors own include Digital Turbine (APPS), Okta (OKTA), Canoo (GOEV), CrowdStrike (CRWD) and NVIDIA (NVDA).

Company Calendar

Last Earnings
8/08/2024
Today
7/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:APTO
CIK
882361
Employees
31
Year Founded
N/A

Price Target and Rating

High Price Target
$6.00
Low Price Target
$6.00
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($89.19)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$51.21 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-5,683.22%
Return on Assets
-300.44%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.05
Quick Ratio
1.05

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.19) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
2,141,000
Free Float
63,446,000
Market Cap
$3.66 million
Optionable
No Data
Beta
1.04

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:APTO) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners